Mohamed Magdi1, Mostafa Reda Mostafa1, Waiel Abusnina2, Ahmad Al-Abdouh3, Ramy Doss4, Sarah Mohamed5, Chidera Philippa Ekpo5, Richard Alweis1, Bipul Baibhav6. 1. Department of Internal Medicine, Rochester Regional Health NY, USA. 2. Department of Cardiology, Creighton University School of Medicine NE, USA. 3. Department of Medicine, University of Kentucky KY, USA. 4. Department of Internal Medicine, Baylor University Medical Center Dallas, Texas. 5. Department of Ophthalmology, Cairo University Cairo, Egypt. 6. Department of Cardiology, Rochester General Hospital NY, USA.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction is a complex clinical syndrome marked by different phenotypes and related comorbidities. Transthyretin amyloidosis is an underestimated phenotype. We aim to evaluate the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction. METHODS: This meta-analysis was conducted according to PRISMA guidelines. A search strategy was designed to utilize PubMed/Medline, EMBASE, and Google scholar to locate studies whose primary objective was to analyze the prevalence of transthyretin amyloidosis in heart failure preserved ejection fraction. RESULTS: Of 271 studies initially identified, 5 studies comprising 670 patients were included in the final analysis. The prevalence of transthyretin amyloidosis was 11%. Patients with transthyretin amyloid cardiomyopathy were more likely to be males (RR 1.38; 95% CI 1.09 to 1.75; P<0.01; I2=37%), and more likely to have low voltage criteria on ECG (RR 2.98; 95% CI 1.03 to 8.58; P=0.04; I2=75%) compared with transthyretin negative group. They also have higher SMD of age (SMD 0.73; 95% CI 0.48 to 0.97; P<0.01; I2=0%), and NT-proBNP (SMD 0.48; 95% CI 0.02 to 0.93; P=0.04; I2=36%) compared with transthyretin negative group. On reported echocardiogram, they have higher SMD of mass index (SMD 0.77; 95% CI 0.27 to 1.27; P<0.01; I2=65%), posterior wall thickness (SMD 0.92; 95% CI 0.62 to 1.21; P<0.01; I2=0%), and septal wall thickness (SMD 1.49; 95% CI 0.65 to 2.32; P<0.01; I2=87%) compared with transthyretin negative group. CONCLUSION: Transthyretin amyloidosis affects 11% of HFpEF patients. Therefore, screening HFpEF patients at risk of cardiac amyloidosis is warranted. AJCD
BACKGROUND: Heart failure with preserved ejection fraction is a complex clinical syndrome marked by different phenotypes and related comorbidities. Transthyretin amyloidosis is an underestimated phenotype. We aim to evaluate the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction. METHODS: This meta-analysis was conducted according to PRISMA guidelines. A search strategy was designed to utilize PubMed/Medline, EMBASE, and Google scholar to locate studies whose primary objective was to analyze the prevalence of transthyretin amyloidosis in heart failure preserved ejection fraction. RESULTS: Of 271 studies initially identified, 5 studies comprising 670 patients were included in the final analysis. The prevalence of transthyretin amyloidosis was 11%. Patients with transthyretin amyloid cardiomyopathy were more likely to be males (RR 1.38; 95% CI 1.09 to 1.75; P<0.01; I2=37%), and more likely to have low voltage criteria on ECG (RR 2.98; 95% CI 1.03 to 8.58; P=0.04; I2=75%) compared with transthyretin negative group. They also have higher SMD of age (SMD 0.73; 95% CI 0.48 to 0.97; P<0.01; I2=0%), and NT-proBNP (SMD 0.48; 95% CI 0.02 to 0.93; P=0.04; I2=36%) compared with transthyretin negative group. On reported echocardiogram, they have higher SMD of mass index (SMD 0.77; 95% CI 0.27 to 1.27; P<0.01; I2=65%), posterior wall thickness (SMD 0.92; 95% CI 0.62 to 1.21; P<0.01; I2=0%), and septal wall thickness (SMD 1.49; 95% CI 0.65 to 2.32; P<0.01; I2=87%) compared with transthyretin negative group. CONCLUSION: Transthyretin amyloidosis affects 11% of HFpEF patients. Therefore, screening HFpEF patients at risk of cardiac amyloidosis is warranted. AJCD
Authors: F Aus dem Siepen; R Bauer; A Voss; S Hein; M Aurich; J Riffel; D Mereles; C Röcken; S J Buss; H A Katus; Arnt V Kristen Journal: Clin Res Cardiol Date: 2017-09-27 Impact factor: 5.460
Authors: Omar F AbouEzzeddine; Daniel R Davies; Christopher G Scott; Ahmed U Fayyaz; J Wells Askew; Paul M McKie; Peter A Noseworthy; Geoffrey B Johnson; Shannon M Dunlay; Barry A Borlaug; Panithaya Chareonthaitawee; Veronique L Roger; Angela Dispenzieri; Martha Grogan; Margaret M Redfield Journal: JAMA Cardiol Date: 2021-11-01 Impact factor: 30.154
Authors: Maarit Tanskanen; Terhi Peuralinna; Tuomo Polvikoski; Irma-Leena Notkola; Raimo Sulkava; John Hardy; Andrew Singleton; Sari Kiuru-Enari; Anders Paetau; Pentti J Tienari; Liisa Myllykangas Journal: Ann Med Date: 2008 Impact factor: 4.709
Authors: Thibaud Damy; Mathew S Maurer; Claudio Rapezzi; Violaine Planté-Bordeneuve; Onur N Karayal; Rajiv Mundayat; Ole B Suhr; Arnt V Kristen Journal: Open Heart Date: 2016-02-08
Authors: Jason N Dungu; Sofia A Papadopoulou; Katharine Wykes; Ihtisham Mahmood; Joseph Marshall; Oswaldo Valencia; Marianna Fontana; Carol J Whelan; Julian D Gillmore; Philip N Hawkins; Lisa J Anderson Journal: Circ Heart Fail Date: 2016-09 Impact factor: 8.790